These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 28906010)

  • 1. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
    Ogasawara N; Kobayashi M; Akuta N; Kominami Y; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Suzuki F; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2018 Feb; 90(2):313-319. PubMed ID: 28906010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Tada T; Kumada T; Toyoda H; Mizuno K; Sone Y; Kataoka S; Hashinokuchi S
    J Gastroenterol Hepatol; 2017 Dec; 32(12):1982-1988. PubMed ID: 28299813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.
    Akuta N; Sezaki H; Suzuki F; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Jan; 89(1):91-98. PubMed ID: 27256744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
    Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
    Akuta N; Toyota J; Karino Y; Ikeda F; Ido A; Tanaka K; Takaguchi K; Naganuma A; Tomita E; Chayama K; Fujiyama S; Inada Y; Yoshiji H; Watanabe H; Ishikawa H; McPhee F; Noviello S; Kumada H
    J Gastroenterol; 2018 Sep; 53(9):1089-1097. PubMed ID: 29500489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study.
    Shin SK; Lee JW; Ra H; Kwon OS; Shin JB; Jin YJ; Lee S; Han KJ; Kim YN; Kim TH; Kim YS; Kim JH
    J Korean Med Sci; 2019 Oct; 34(41):e264. PubMed ID: 31650719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
    Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
    Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination.
    Tamori A; Hai H; Uchida-Kobayashi S; Enomoto M; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Teranishi Y; Yoshida K; Morikawa H; Murakami Y; Kawada N
    Ann Hepatol; 2017; 16(5):734-741. PubMed ID: 28809743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of liver stiffness values by means of transient elastography in patients with HCV liver cirrhosis undergoing interferon free treatment.
    Sporea I; Lupușoru R; Mare R; Popescu A; Gheorghe L; Iacob S; Șirli R
    J Gastrointestin Liver Dis; 2017 Jun; 26(2):145-150. PubMed ID: 28617884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.
    Lee YC; Hu TH; Hung CH; Lu SN; Chen CH; Wang JH
    PLoS One; 2019; 14(4):e0214323. PubMed ID: 30939158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.
    Wei L; Wang FS; Zhang MX; Jia JD; Yakovlev AA; Xie W; Burnevich E; Niu JQ; Jung YJ; Jiang XJ; Xu M; Chen XY; Xie Q; Li J; Hou JL; Tang H; Dou XG; Gandhi Y; Hu WH; McPhee F; Noviello S; Treitel M; Mo L; Deng J
    World J Gastroenterol; 2018 Mar; 24(12):1361-1372. PubMed ID: 29599611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
    Yu JH; Lee JI; Lee KS; Kim JK
    Virol J; 2017 Aug; 14(1):164. PubMed ID: 28836992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
    Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hirooka Y; Toyoda H; Kumada T; Hattori M; Katano Y; Goto H
    J Viral Hepat; 2018 Dec; 25(12):1446-1451. PubMed ID: 29993164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
    Uchida Y; Naiki K; Kouyama JI; Sugawara K; Nakao M; Motoya D; Inao M; Nakayama N; Imai Y; Tomiya T; Mochida S
    PLoS One; 2018; 13(10):e0205600. PubMed ID: 30308053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Lok AS; Gardiner DF; Hézode C; Lawitz EJ; Bourlière M; Everson GT; Marcellin P; Rodriguez-Torres M; Pol S; Serfaty L; Eley T; Huang SP; Li J; Wind-Rotolo M; Yu F; McPhee F; Grasela DM; Pasquinelli C
    J Hepatol; 2014 Mar; 60(3):490-9. PubMed ID: 24444658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
    Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
    Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy.
    Tada T; Kumada T; Toyoda H; Sone Y; Takeshima K; Ogawa S; Goto T; Wakahata A; Nakashima M; Nakamuta M; Tanaka J
    Aliment Pharmacol Ther; 2018 Apr; 47(7):1012-1022. PubMed ID: 29424449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry.
    Knop V; Mauss S; Goeser T; Geier A; Zimmermann T; Herzer K; Postel N; Friedrich-Rust M; Hofmann WP;
    J Viral Hepat; 2020 Jul; 27(7):690-698. PubMed ID: 32096310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.